安省的指引
• ≥70 year olds • Residents of longterm care homes, retirement homes or seniors in other congregate settings • Moderately to severely immunocompromised adults (for 3 rd dose as part of the primary series Either Moderna or Pfizer-BioNTech (30mcg) may be considered. If Moderna vaccine is being used as the booster product, a 100 mcg dose may be preferred, based on clinical discretion. Moderna (100 mcg) induces somewhat higher antibody levels compared to Pfizer-BioNTech (30 mcg). Protection (against infection and severe disease) from a primary series with Moderna (100 mcg) may be more durable than Pfizer (30mcg). These populations may have less robust immune function (elderly) or a diminished immune response to the vaccine (some immunocompromised individuals). It is possible that Moderna (100 mcg) may induce a better immune response than Moderna (50 mcg).